Review Article | Published:

Ribosome-targeting antibiotics and mechanisms of bacterial resistance

Nature Reviews Microbiology volume 12, pages 3548 (2014) | Download Citation

Abstract

The ribosome is one of the main antibiotic targets in the bacterial cell. Crystal structures of naturally produced antibiotics and their semi-synthetic derivatives bound to ribosomal particles have provided unparalleled insight into their mechanisms of action, and they are also facilitating the design of more effective antibiotics for targeting multidrug-resistant bacteria. In this Review, I discuss the recent structural insights into the mechanism of action of ribosome-targeting antibiotics and the molecular mechanisms of bacterial resistance, in addition to the approaches that are being pursued for the production of improved drugs that inhibit bacterial protein synthesis.

Key points

  • The bacterial ribosome is one of the main targets of antibiotics, with most clinically used antibiotics targeting either the decoding site on the small ribosomal subunit (30S subunit) or the peptidyl-transferase centre on the large subunit (50S subunit).

  • The majority of antibiotics that target the 30S subunit inhibit protein synthesis by preventing either the binding of tRNAs to the ribosome or the movement of tRNAs through the ribosome during translocation.

  • Most antibiotics that target the 50S subunit inhibit protein synthesis by either perturbing the binding of aminoacylated-tRNAs at the A- or P-sites or preventing the channelling of the nascent polypeptide chain through the ribosomal tunnel.

  • Bacterial antibiotic resistance mechanisms include efflux, reduced influx, modification and degradation of the drug, as well as mutation, modification or overexpression of the target.

  • The majority of ribosome-targeting antibiotics in clinical trials are semi-synthetic derivatives of naturally produced compounds, but further work will be required to develop antibiotics that target novel sites on the ribosome.

  • Subscribe to Nature Reviews Microbiology for full access:

    $265

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    & Structural basis of the translational elongation cycle. Annu. Rev. Biochem. 82, 203–236 (2013).

  2. 2.

    Where will new antibiotics come from? Nature Rev. Microbiol. 1, 65–70 (2003).

  3. 3.

    & The bacterial ribosome as a target for antibiotics. Nature Rev. Microbiol. 3, 870–881 (2005).

  4. 4.

    The A-Z of bacterial translation inhibitors. Crit. Rev. Biochem. Mol. Biol. 44, 393–433 (2009). A comprehensive overview of the mechanism of action of antibiotics that target the bacterial translation apparatus.

  5. 5.

    , , & SnapShot: Antibiotic inhibition of protein synthesis I. Cell 138, 1248 e1241 (2009).

  6. 6.

    , & Distinct functions of elongation factor G in ribosome recycling and translocation. RNA 15, 772–780 (2009).

  7. 7.

    , , & Blasticidin S inhibits translation by trapping deformed tRNA on the ribosome. Proc. Natl Acad. Sci. USA 110, 12283–12288 (2013).

  8. 8.

    et al. Structure of the 70S ribosome complexed with mRNA and tRNA. Science 313, 1935–1942 (2006). The high-resolution crystal structure of the T. thermophilus 70S ribosome reported in this study opened the way to structures of T. thermophilus 70S–antibiotic complexes, such as those reported in references 7, 18, 29, 30 and 40.

  9. 9.

    et al. Structures of the bacterial ribosome at 3.5 Å resolution. Science 310, 827–834 (2005). The high-resolution crystal structure of the E. coli 70S ribosome reported here opened the way to structures of E. coli 70S–antibiotic complexes, such as those reported in references 24, 25, 41, 139 and 141.

  10. 10.

    , , , & A novel site of antibiotic action in the ribosome: interaction of evernimicin with the large ribosomal subunit. Proc. Natl Acad. Sci. USA 98, 3726–3731 (2001).

  11. 11.

    et al. Differential effects of thiopeptide and orthosomycin antibiotics on translational GTPases. Chem. Biol. 18, 589–600 (2011).

  12. 12.

    & Antibiotics for emerging pathogens. Science 325, 1089–1093 (2009).

  13. 13.

    et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 103, 1143–1154 (2000). This study, together with references 14, 20 and 142, reports the first structures of antibiotics in complex with the 30S subunit.

  14. 14.

    et al. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 20, 1829–1839 (2001).

  15. 15.

    Update on acquired tetracycline resistance genes. FEMS Microbiol. Lett. 245, 195–203 (2005).

  16. 16.

    et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob. Agents Chemother. 50, 2156–2166 (2006).

  17. 17.

    et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob. Agents Chemother. 56, 2559–2564 (2012).

  18. 18.

    et al. Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc. Natl Acad. Sci. USA 110, 3812–3816 (2013).

  19. 19.

    , , & Structure of the A-site of E. coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274, 1367–1371 (1996).

  20. 20.

    et al. Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 292, 897–902 (2001).

  21. 21.

    & Structural insights into translational fidelity. Annu. Rev. Biochem. 74, 129–177 (2005).

  22. 22.

    , , , & A new understanding of the decoding principle on the ribosome. Nature 484, 256–259 (2012).

  23. 23.

    et al. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc. Natl Acad. Sci. USA 109, 10984–10989 (2012).

  24. 24.

    et al. Structural basis for aminoglycoside inhibition of bacterial ribosome recycling. Nature Struct. Mol. Biol. 14, 727–732 (2007).

  25. 25.

    et al. Allosteric control of the ribosome by small-molecule antibiotics. Nature Struct. Mol. Biol. 19, 957–963 (2012).

  26. 26.

    , & Inhibition of ribosomal translocation by aminoglycoside antibiotics. Biochem. Biophys. Res. Commun. 83, 991–997 (1978).

  27. 27.

    , , & Interaction of kanamycin and related antibiotics with the large subunit of ribosomes and the inhibition of translocation. Biochem. Biophys. Res. Commun. 84, 358–365 (1978).

  28. 28.

    , , & Aminoglycoside activity observed on single pre-translocation ribosome complexes. Nature Chem. Biol. 6, 54–62 (2010).

  29. 29.

    , , , & The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nature Struct. Mol. Biol. 17, 289–293 (2010).

  30. 30.

    , & The antibiotic thermorubin inhibits protein synthesis by binding to inter-subunit bridge B2a of the ribosome. J. Mol. Biol. 416, 571–578 (2012).

  31. 31.

    & Multidrug-resistant to extensively drug resistant tuberculosis: what is next? J. Biosci. 33, 605–616 (2008).

  32. 32.

    & The inhibition of ribosomal translocation by viomycin. Eur. J. Biochem. 81, 491–497 (1977).

  33. 33.

    et al. The antibiotic viomycin traps the ribosome in an intermediate state of translocation. Nature Struct. Mol. Biol. 14, 493–497 (2007).

  34. 34.

    , , & Spontaneous intersubunit rotation in single ribosomes. Mol. Cell 30, 578–588 (2008).

  35. 35.

    et al. Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin. Antimicrob. Agents Chemother. 55, 4712–4717 (2011).

  36. 36.

    , & Synthesis and antibacterial activity of some derivatives of the antibiotic thermorubin. J. Antibiot. (Tokyo) 38, 1752–1760 (1985).

  37. 37.

    & The protein synthesis inhibitor thermorubin. 1. Nature of the thermorubin-ribosome complex. Biochemistry 21, 477–483 (1982).

  38. 38.

    & The protein synthesis inhibitor thermorubin. 2. Mechanism of inhibition of initiation on Escherichia coli ribosomes. Biochemistry 21, 484–491 (1982).

  39. 39.

    On the specificity of antibiotics targeting the large ribosomal subunit. Ann. NY Acad. Sci. 1241, 1–16 (2011).

  40. 40.

    , , & Revisiting the structures of several antibiotics bound to the bacterial ribosome. Proc. Natl Acad. Sci. USA 107, 17158–17163 (2010).

  41. 41.

    , , & Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc. Natl Acad. Sci. USA 107, 17152–17157 (2010). References 40 and 41 reveal that macrolides bind to bacterial ribosomes, as reported previously for the archaeal 50S subunit. However, the data obtained question the validity of the conformation of macrolides and chloramphenicol reported in the earlier bacterial D. radiodurans structures (for example, reference 46).

  42. 42.

    , & Elements of ribosomal drug resistance and specificity. Curr. Opin. Struct. Biol. 22, 750–758 (2013).

  43. 43.

    et al. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol. Cell 10, 117–128 (2002). Together with references 46 and 47, this study reports the first structures of antibiotics in complex with the 50S subunit.

  44. 44.

    , , & Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 121, 257–270 (2005).

  45. 45.

    , , & Structures of triacetyloleandomycin and mycalamide A bind to the large ribosomal subunit of Haloarcula marismortui. Antimicrob. Agents Chemother. 53, 5010–5014 (2009).

  46. 46.

    et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814–821 (2001).

  47. 47.

    , & Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J. Mol. Biol. 330, 1061–1075 (2003).

  48. 48.

    & Chloramphenicol resistance mutations in the single 23S rRNA gene of the archaeon Halobacterium halobium. J. Bacteriol. 173, 3559–3563 (1991).

  49. 49.

    The other target for ribosomal antibiotics: inhibition of bacterial ribosomal subunit formation. Infect. Disord. Drug Targets 6, 377–390 (2006).

  50. 50.

    et al. Antibiotic-induced ribosomal assembly defects result from changes in the synthesis of ribosomal proteins. Mol. Microbiol. 80, 54–67 (2011).

  51. 51.

    et al. Erythromycin- and chloramphenicol-induced ribosomal assembly defects are secondary effects of protein synthesis inhibition. Antimicrob. Agents Chemother. 53, 563–571 (2009).

  52. 52.

    et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell 26, 393–402 (2007).

  53. 53.

    et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc. Natl Acad. Sci. USA 105, 13339–13344 (2008).

  54. 54.

    et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51, 3353–3356 (2008). References 52–54 show excellent agreement for the binding position of the oxazolidinone linezolid at the PTC of bacterial and archaeal ribosomes.

  55. 55.

    & Catalysis of ribosomal translocation by sparsomycin. Science 300, 1159–1162 (2003).

  56. 56.

    , , & Linezolid, the first oxazolidinone antibacterial agent. Ann. NY Acad. Sci. 1222, 49–54 (2011).

  57. 57.

    & Structure-based drug design meets the ribosome. Biochem. Pharmacol. 71, 1016–1025 (2006).

  58. 58.

    , , & Sparsomycin-linezolid conjugates can promote ribosomal translocation. Chembiochem 12, 2801–2806 (2011).

  59. 59.

    , , & Antibiotics that bind to the A site of the large ribosomal subunit can induce mRNA translocation. RNA 19, 158–166 (2013).

  60. 60.

    & Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. Ann. NY Acad. Sci. 1241, 33–47 (2012).

  61. 61.

    et al. Structural insight into the antibiotic action of telithromycin on resistant mutants. J. Bact. 185, 4276–4279 (2003).

  62. 62.

    , , , & Species-specific antibiotic-ribosome interactions: Implications for drug development. Biol. Chem. 386, 1239–1252 (2005).

  63. 63.

    , & The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Mol. Biol. 330, 1005–1014 (2003).

  64. 64.

    , , & Erythromycin resistance peptides selected from random peptide libraries. J. Biol. Chem. 272, 17425–17430 (1997).

  65. 65.

    , & Programmed drug-dependent ribosome stalling. Mol. Microbiol. 71, 811–824 (2009).

  66. 66.

    , & Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell 151, 508–520 (2012). This work demonstrates that macrolide antibiotics allow the synthesis of a small subset of proteins, thus conceptually changing our mechanistic understanding of the mechanism of action of this clinically important class of antibiotics.

  67. 67.

    & Mechanism of action of streptogramins and macrolides. Drugs 51, 20–30 (1996).

  68. 68.

    , , , & Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol. 2, 4 (2004). Together with references 44 and 69–70, this study provides a structural basis for the synergistic activity of the streptogramin class of antibiotics.

  69. 69.

    et al. The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics. Proc. Natl Acad. Sci. USA 107, 1983–1988 (2010).

  70. 70.

    et al. Crystal structure of the synergistic antibiotic pair, lankamycin and lankacidin, in complex with the large ribosomal subunit. Proc. Natl Acad. Sci. USA 108, 2717–2122 (2011).

  71. 71.

    et al. Antibiotic resistance is ancient. Nature 477, 457–461 (2011).

  72. 72.

    & Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417–433 (2010).

  73. 73.

    et al. The shared antibiotic resistome of soil bacteria and human pathogens. Science 337, 1107–1111 (2012).

  74. 74.

    et al. Call of the wild: antibiotic resistance genes in natural environments. Nature Rev. Microbiol. 8, 251–259 (2010).

  75. 75.

    et al. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 467, 991–994 (2010).

  76. 76.

    et al. Structures of a Na+-coupled, substrate-bound MATE multidrug transporter. Proc. Natl Acad. Sci. USA 110, 2099–2104 (2013).

  77. 77.

    et al. Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 496, 247–251 (2013).

  78. 78.

    Structural biology: last of the multidrug transporters. Nature 467, 926–927 (2010).

  79. 79.

    Multidrug-resistance efflux pumps — not just for resistance. Nature Rev. Microbiol. 4, 629–636 (2006).

  80. 80.

    et al. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc. Natl Acad. Sci. USA 104, 4291–4296 (2007).

  81. 81.

    et al. Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol. Cell 30, 26–38 (2008).

  82. 82.

    et al. The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147L. Antimicrob. Agents Chemother. 57, 1173–1179 (2013).

  83. 83.

    , , , & Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics 12, 512 (2011).

  84. 84.

    & Sites of action of two ribosomal RNA methylases responsible for resistance to aminoglycosides. J. Mol. Biol. 193, 661–671 (1987).

  85. 85.

    How antibiotic-producing organisms avoid suicide. Ann. Rev. Microbiol. 43, 207–233 (1989).

  86. 86.

    et al. Identification of 8-methyladenosine as the modification catalyzed by the radical SAM methyltransferase Cfr that confers antibiotic resistance in bacteria. RNA 15, 327–336 (2009).

  87. 87.

    , , , & The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob. Agents Chemother. 50, 2500–2505 (2006).

  88. 88.

    & Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. Antimicrob. Agents Chemother. 52, 1703–1712 (2008).

  89. 89.

    , , & Low fitness cost of the multidrug resistance gene cfr. Antimicrob. Agents Chemother. 55, 3714–3719 (2011).

  90. 90.

    , , & Deregulation of translation due to post-transcriptional modification of rRNA explains why erm genes are inducible. Nature Commun. 4, 1984 (2013).

  91. 91.

    , , & Capreomycin susceptibility is increased by TlyA-directed 2′-O-methylation on both ribosomal subunits. Mol. Microbiol. 85, 1194–1203 (2012).

  92. 92.

    , & Inactivation of the indigenous methyltransferase RlmN in Staphylococcus aureus increases linezolid resistance. Antimicrob. Agents Chemother. 55, 2989–2991 (2011).

  93. 93.

    et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol. Microbiol. 63, 1096–1106 (2007).

  94. 94.

    & The selection in vivo and characterization of an RNA recognition motif for spectinomycin. Bioorgan. Med. Chem. 5, 1081–1086 (1997).

  95. 95.

    et al. Amythiamicin D and related thiopeptides as inhibitors of the bacterial elongation factor EF-Tu: modification of the amino acid at carbon atom C2 of ring C dramatically influences the activity. Eur. J. Biochem. (2013).

  96. 96.

    , , & Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob. Agents Chemother. 47, 3675–3681 (2003).

  97. 97.

    & Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol. Microbiol. 59, 664–676 (2006).

  98. 98.

    et al. Structural basis for TetM-mediated tetracycline resistance. Proc. Natl Acad. Sci. USA 109, 16900–16905 (2012).

  99. 99.

    et al. Mechanism of tetracycline resistance by ribosomal protection protein Tet(O). Nature Commun. 4, 1477 (2013). References 98 and 99 report structures of ribosome protection proteins on the ribosome, revealing that these factors confer tetracycline resistance by directly dislodging tetracycline from its ribosomal binding site rather than by an indirect mechanism as previously proposed.

  100. 100.

    et al. Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid. Proc. Natl Acad. Sci. USA 109, 2102–2107 (2012).

  101. 101.

    et al. Structure and function of FusB: an elongation factor G-binding fusidic acid resistance protein active in ribosomal translocation and recycling. Open Biol. 2, 120016 (2012).

  102. 102.

    Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv. Drug Deliv. Rev. 57, 1451–1470 (2005).

  103. 103.

    & Aminoglycoside modifying enzymes. Drug Resist. Updat. 13, 151–171 (2010).

  104. 104.

    et al. Inactivation of chloramphenicol by O-phosphorylation. A novel resistance mechanism in Streptomyces venezuelae ISP5230, a chloramphenicol producer. J. Biol. Chem. 270, 27000–27006 (1995).

  105. 105.

    et al. Phosphorylation of chloramphenicol by a recombinant protein Yhr2 from Streptomyces avermitilis MA4680. Bioorg. Med. Chem. Lett. 23, 3614–3619 (2013).

  106. 106.

    , & An O-phosphotransferase catalyzes phosphorylation of hygromycin A in the antibiotic-producing organism Streptomyces hygroscopicus. Antimicrob. Agents Chemother. 52, 3580–3588 (2008).

  107. 107.

    , , , & Structural basis for a new tetracycline resistance mechanism relying on the TetX monooxygenase. FEBS Lett. 585, 1061–1066 (2011).

  108. 108.

    , & Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry 44, 11829–11835 (2005).

  109. 109.

    , & Chemical decay of an antibiotic inverts selection for resistance. Nature Chem. Biol. 6, 105–107 (2010).

  110. 110.

    & Antibiotics in the clinical pipeline in 2011. J. Antibiot. (Tokyo) 64, 413–425 (2011).

  111. 111.

    Antibiotics in development targeting protein synthesis. Ann. NY Acad. Sci. 1241, 122–152 (2011).

  112. 112.

    & Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin. Drug Discov. 5, 883–902 (2010).

  113. 113.

    & Recent developments on ketolides and macrolides. Curr. Med. Chem. 8, 1727–1758 (2001).

  114. 114.

    , , & Recent advances in the chemistry and biology of naturally occurring antibiotics. Angew. Chem. Int. Ed Engl. 48, 660–719 (2009).

  115. 115.

    , & Thiazolyl peptide antibiotic biosynthesis: a cascade of post-translational modifications on ribosomal nascent proteins. J. Biol. Chem. 285, 27525–27531 (2010).

  116. 116.

    et al. Specific, efficient, and selective inhibition of prokaryotic translation initiation by a novel peptide antibiotic. Proc. Natl Acad. Sci. USA 103, 39–44 (2006).

  117. 117.

    , & Selection of small peptides, inhibitors of translation. J. Mol. Biol. 391, 813–819 (2009).

  118. 118.

    et al. Structural and functional characterization of the bacterial translocation inhibitor GE82832. FEBS Lett. 586, 3373–3378 (2012).

  119. 119.

    et al. The antibiotic Furvina® targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. 40, 10366–10374 (2012).

  120. 120.

    et al. Orthoformimycin, a selective inhibitor of bacterial translation elongation from Streptomyces containing an unusual orthoformate. ACS Chem. Biol. 8, 1939–1946 (2013).

  121. 121.

    , , , & The structures of antibiotics bound to the E site region of the 50 S ribosomal subunit of Haloarcula marismortui: 13-deoxytedanolide and girodazole. J. Mol. Biol. 367, 1471–1479 (2007).

  122. 122.

    et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nature Chem. Biol. 6, 209–217 (2010).

  123. 123.

    , , , & Crystal structure of the eukaryotic 60S ribosomal subunit in complex with initiation factor 6. Science 334, 941–948 (2011). The structures of eukaryotic ribosomes reported in this work and in references 124–126 open the way to investigating the specificity of antibiotic interactions with the ribosome, as well as the development of anticancer drugs.

  124. 124.

    et al. The structure of the eukaryotic ribosome at 3.0 Å resolution. Science 334, 1524–1529 (2011).

  125. 125.

    , , , & Crystal structure of the eukaryotic 40S ribosomal subunit in complex with initiation factor 1. Science 331, 730–736 (2011).

  126. 126.

    et al. Structures of the human and Drosophila 80S ribosome. Nature 497, 80–85 (2013).

  127. 127.

    , , & Suppression of premature termination codons as a therapeutic approach. Crit. Rev. Biochem. Mol. Biol. 47, 444–463 (2012).

  128. 128.

    , , , & Translocation of tRNA during protein synthesis. FEBS Letter 514, 11–16 (2002).

  129. 129.

    & The ribosome as a molecular machine: the mechanism of tRNA-mRNA movement in translocation. Biochem. Soc. Trans. 39, 658–662 (2011).

  130. 130.

    , , , & Unraveling the dynamics of ribosome translocation. Curr. Opin. Struct. Biol. 22, 804–814 (2013).

  131. 131.

    & Intermediate states in the movement of transfer RNA in the ribosome. Nature 342, 142–148 (1989).

  132. 132.

    , , & Identification of two distinct hybrid state intermediates on the ribosome. Mol. Cell 25, 505–517 (2007).

  133. 133.

    et al. Visualization of the hybrid state of tRNA binding promoted by spontaneous ratcheting of the ribosome. Mol. Cell 32, 190–197 (2008).

  134. 134.

    et al. Structure of ratcheted ribosomes with tRNAs in hybrid states. Proc. Natl Acad. Sci. USA 105, 16924–16927 (2008).

  135. 135.

    & Ratchet-like movements between the two ribosomal subunits: their implications in elongation factor recognition and tRNA translocation. Cold Spring Harb. Symp. Quant. Biol. 66, 67–75 (2001).

  136. 136.

    , , , & Coordinated conformational and compositional dynamics drive ribosome translocation. Nature Struct. Mol. Biol. 20, 718–727 (2013).

  137. 137.

    et al. An elongation factor G-induced ribosome rearrangement precedes tRNA-mRNA translocation. Mol. Cell 11, 1517–1523 (2003).

  138. 138.

    et al. Head swivel on the ribosome facilitates translocation by means of intra-subunit tRNA hybrid sites. Nature 468, 713–716 (2010).

  139. 139.

    , , , & A steric block in translation caused by the antibiotic spectinomycin. ACS Chem. Biol. 2, 545–552 (2007).

  140. 140.

    et al. The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nature Struct. Mol. Biol. 13, 871–878 (2006).

  141. 141.

    , , & Structural basis for hygromycin B inhibition of protein biosynthesis. RNA 14, 1590–1599 (2008).

  142. 142.

    et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407, 340–348 (2000).

  143. 143.

    , , & Structural insights into peptide bond formation. Proc. Natl Acad. Sci. USA 99, 11670–11675 (2002).

  144. 144.

    , , , & Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol. 54, 1287–1294 (2004).

  145. 145.

    et al. Structural insight into nascent polypeptide chain-mediated translational stalling. Science 326, 1412–1415 (2009).

Download references

Acknowledgements

I give special thanks to A. Mankin, B. Beatrix and members of my laboratory for critical reading of the manuscript. I also thank the Deutsche Forschungsgemeinschaft (WI3285/2-1) and the EMBO young investigator grant for funding research related to this topic.

Author information

Affiliations

  1. Gene Center and Department for Biochemistry, Feodor-Lynenstr. 25, University of Munich, 81377 Munich, Germany.

    • Daniel N. Wilson
  2. Center for integrated Protein Science Munich (CiPSM), Feodor-Lynenstr. 25, University of Munich, 81377 Munich, Germany.

Authors

  1. Search for Daniel N. Wilson in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to Daniel N. Wilson.

Glossary

Peptidyl-transferase centre

(PTC). The site of peptide-bond formation on the large subunit, comprising universally conserved residues of domain V of the 23S ribosomal RNA.

Classical tRNA state

The tRNA binding state in which the anticodon and acceptor arms of the tRNA occupy the same sites on the 30S and 50S subunit, respectively.

Stacking interaction

Non-covalent interaction established by parallel plate stacked orientation of two moieties, with at least one being aromatic.

Non-cognate tRNAs

tRNAs that have a mismatched base-pairing interaction with mRNA codons. Accommodation leads to misincorporation of an incorrect amino acid into the nascent polypeptide chain.

Decoding centre

The A-site region of the small ribosomal subunit that is responsible for discriminating cognate from non-cognate tRNAs based on anticodon–codon interactions. This site encompasses the universally conserved nucleotides A1492 and A1493 of helix 44 of the 16S rRNA.

Cognate tRNAs

tRNAs that have a matched base-pairing interaction with mRNA codons. Accommodation leads to incorporation of the correct amino acid into the nascent polypeptide chain.

Intersubunit bridges

Sites of interaction at the interface between the small and large ribosomal subunits.

Hybrid state

The tRNA binding state in which the anticodon and acceptor arms of the tRNA occupy different sites on the 30S and 50S subunit, respectively.

Peptidyl-tRNA drop-off

Dissociation of tRNAs bearing the nascent polypeptide chain from the ribosome.

Bacteriocidal

Bacteriocidal antibiotics induce cell death, as exemplified by the aminoglycoside class of ribosome-targeting antibiotics.

Bacteriostatic

Bacteriostatic antibiotics inhibit bacterial growth but do not induce cell death, such that removal of the antibiotic leads to restoration of growth. Most ribosome-targeting antibiotics are bacteriostatic.

MATE family of transporters

(Multidrug and toxic compound extrusion family of transporters). MATE transporters couple antibiotic efflux (against their prevailing concentration gradient) to the energetically favourable movement of sodium ions (Na+) into the cell (along their electrochemical gradient).

Porins

β-barrel proteins that span the cell membrane and act as pores through which molecules can diffuse.

Compensatory mutations

In the context of this Review, secondary mutations that arise to restore bacterial fitness following a decrease in fitness owing to antibiotic resistance mutations.

Translation profiles

An indication of the changes in the levels of synthesis of proteins by ribosomes.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrmicro3155

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.